June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Sustained release of ovalbumin and IgG from hydrogel depots as surrogate proteins for intravitreal injection
Author Affiliations & Notes
  • Rami Elhayek
    Ocular Therapeutix, BEDFORD, MA
  • Rami Elhayek
    Ocular Therapeutix, BEDFORD, MA
  • Peter Jarrett
    Ocular Therapeutix, BEDFORD, MA
  • Amar Sawhney
    Ocular Therapeutix, BEDFORD, MA
  • Sarah Guedez
    Ocular Therapeutix, BEDFORD, MA
  • Footnotes
    Commercial Relationships Rami Elhayek, OCULAR THERAPEUTIX INC (E); Rami Elhayek, OCULAR THERAPEUTIX INC (E); Peter Jarrett, Ocular Therapeutix (E); Amar Sawhney, Ocular Therapeutix (E); Sarah Guedez, Ocular Therapeutix (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1095. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rami Elhayek, Rami Elhayek, Peter Jarrett, Amar Sawhney, Sarah Guedez; Sustained release of ovalbumin and IgG from hydrogel depots as surrogate proteins for intravitreal injection. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1095.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To evaluate the sustained release of ovalbumin (OVA; 45000 g/mol) and rabbit IgG (rIgG; 150000 g/mol) from preformed hydrogel depots with variable degradation times.


: Fine particles of OVA and IgG were formulated with a selection of PEG hydrogels and were cured, dried and cut to form degradable (a, b, c, d) and non-degradable (e) hydrogel depots. The depots were examined in vitro for sustained release under accelerated conditions. Prior to testing, acceleration rate was calculated using degradation profiles of each hydrogel, absent of OVA and IgG, to compare the relative degradation rate between accelerated and real-time conditions, tris buffer saline (TBS) pH8.5 and phosphate buffer saline (PBS) pH7.4, respectively. Acceleration factor was determined to be 16x in TBS compared to PBS. Accelerated OVA and IgG in vitro release was conducted to determine release profiles as a function of the hydrogel degradation over time. Concentration of OVA and rIgG were determined by HPLC.


Release profiles of OVA and rIgG shown in Figure 1 and 2 show the effect of hydrogel degradation time on sustained release of OVA and rIgG. Slow degrading hydrogels release OVA and rIgG over a longer time period than faster degrading hydrogels. Comparison of OVA and rIgG release using the same hydrogels indicate that rIgG is released slower than OVA due the difference in size and molecular weight. In both cases, hydrogels made using non-degradable SGA linkages used as controls reach a maximum release after diffusion of surface and free particles.


Monoclonal antibody fragments and fusion proteins have been designed to inhibit vascular endothelial growth factors (VEGF) for treatment of posterior segment diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME). Frequent anti-VEGF intravitreal injections have shown to manage the progression of these diseases to prevent further vision loss and in some cases, gain visual acuity. However, frequent intravitreal injections can increase the risk of infection, retinal detachment, and/or hemorrhage. The ability to tailor the release of OVA and rIgG from hydrogel depots for sustained delivery of proteins could provide a technology platform for use with anti-VEGFs to reduce the number of yearly intravitreal injections and potentially reduce the risk of side effects.

Keywords: 561 injection • 748 vascular endothelial growth factor • 763 vitreous  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.